|
| Nanocarriers (composition) | Particle diameters | Strategies of cancer targeting | Loaded drugs | Refs. |
|
| Nanoparticles (alginate/chitosan) | 212-552 nm | Enhanced cellular uptake | Curcumin diglutaric acid | [91] |
| Nanoparticles (alginate/chitosan) | ~80 nm | Enhanced cellular uptake | Doxorubicin | [92] |
| Nanoparticles (PLGA/alginate/chitosan) | Below 200 nm | EPR effect | Doxorubicin | [93] |
| Nanoparticles (PLGA/alginate/chitosan) | 200 nm | Folic acid receptor-based endocytosis | | [94] |
| Nanoparticles (alginate/chitosan) | 115 nm | Folic acid receptor-based endocytosis | 5-Aminolevulinic acid | [95] |
| Nanoparticles (alginate) | 274.2 nm | Glycyrrhetinic acid-mediated endocytosis | Doxorubicin | [96] |
| Nanoparticles (iron oxide/alginate/hydroxyapatite) | 9.6-20 nm | pH-responsive | Curcumin and 6-gingerol | [97] |
| Nanoparticles (mesoporous silica/alginate) | ∼100 nm | Redox and pH dual-responsive | Doxorubicin | [98] |
| Nanoparticles (MnFe2O4/alginate/chitosan) | ~200 nm | Magneto-responsive | Curcumin | [99] |
| Nanogels (alginate-cyclodextrin) | ~55.1 nm | Pressure-sensitive | 5-Fluorouracil | [31] |
| Nanogels (alginate) | ~250 nm | Folic acid receptor-based endocytosis | Doxorubicin | [100] |
| Nanogels (alginate/keratin) | ~100 nm | GSH/trypsin-responsive | Doxorubicin | [101] |
| Micelles (alginate-graft-poly(N-isopropylacrylamide)) | 30-300 nm | pH, ionic strength, or temperature-sensitive | 5-Fluorouracil | [77] |
| Micelles (alginate-curcumin conjugate) | 200 nm | Enhanced cellular uptake | Curcumin | [79] |
| Micelle (alginate-curcumin conjugate) | 235 nm | ASGPR-mediated endocytosis | Curcumin | [78] |
| Liposomes (alginate-cisplatin conjugate) | 110 nm | Epidermal growth factor receptor-mediated endocytosis | Cisplatin | [102] |
| Nanohybrids (alginate-doxorubicin conjugate) | ~142 nm | pH-responsive | Doxorubicin | [103] |
| Nanodroplets (alginate) | ~55.1 nm | Ultrasound-responsive | Doxorubicin/curcumin | [104] |
| Nanodroplets (alginate) | ~51.7 nm | Ultrasound-responsive | Doxorubicin | [105] |
| Nanocomplexes (alginate/chitosan) | 70-120 nm | Folic acid receptor-based endocytosis | Temozolomide and doxorubicin | [106] |
|
